Enliven Therapeutics appoints Scott Garland to board; Phillips resigns as ELVN prepares for Phase 3

Enliven Therapeutics, Inc.

Scott Garland appointed as Class I director and Chair of Nominating and Corporate Governance Committee effective Jan 7, 2026.
Garland receives $40k annual cash (director) + $10k (committee chair) and initial stock option grant with ~$650k fair value vesting over 3 years.
Andrew Phillips resigned from board and committees effective Jan 7, 2026; resignation not due to any disagreement with company.
Garland brings biopharma commercial expertise as company advances ELVN-001 toward Phase 3 pivotal trial in CML in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.